An observational study in Gastric Cancer, Gastric (Stomach) Cancer and Gastric Cancer (Diagnosis), sponsored by Société Algérienne de Formation et Recherche en Oncologie. Recruiting at 15 sites in Algeria. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Société Algérienne de Formation et Recherche en Oncologie · Observational
The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with gastric cancer.
It also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria.
This is a non-interventional, observational, descriptive, cross-sectional clinical study with both prospective and retrospective data collection. It aims to describe the demographic, epidemiological, clinical, and outcome characteristics of approximately 1,000 patients with histologically confirmed gastric cancer in Algeria, and to analyze diagnostic and treatment practices.
Data will be collected from medical records and brief patient interviews (≈30 minutes). All information will be anonymized and used exclusively for research purposes.
3,399 studies on the registry are indexed under Stomach Neoplasms; 992 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 278 across 790 observational studies indexed under Stomach Neoplasms.
Browse Stomach Neoplasms studies →Société Algérienne de Formation et Recherche en Oncologie is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with histologically confirmed gastric cancer, followed in the participating oncology departments.
Inclusion Criteria:
Non Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Demographic characteristics of patients with gastric cancer in Algeria
The patient's demographic profile will include age (years) and sex. Body Mass Index (BMI) will be calculated using weight (kg) and height (m) according to the formula BMI = weight / height² (kg/m²).
Time frame: At Baseline ( Initial visit )
Sociological characteristics of patients with gastric cancer in Algeria
The patient's sociological profile will be described as a composite variable : Education level (primary, secondary, university, other), Profession (employed, unemployed, retired, student, other), Place of residence (current residence; urban or rural), Origin (wilaya of birth/origin)
Time frame: At Baseline ( Initial visit )
Epidemiological characteristics of patients with gastric cancer in Algeria.
Frequency (%) of epidemiological risk factors including family history of cancer, Helicobacter pylori infection, smoking status, alcohol consumption, dietary habits, and exposure to chemical substances.
Time frame: At Baseline (Initial Visit)
Clinical characteristics of patients with gastric cancer in Algeria.
Distribution of patients according to initial symptoms, tumor localization, histological characteristics, biomarker expression, presence of metastases, and tumor stage according to the AJCC classification.
Time frame: At Basline ( Initial Visit)
Evolutionary characteristics of patients with gastric cancer.
Distribution of treatment modalities including surgery (palliative or curative) and chemotherapy (adjuvant or treatment lines), as well as treatment response, complications, disease-free survival (DFS), and duration of response.
Time frame: At Baseline ( Initial Visit)
Diagnostic modalities in patients with gastric cancer in Algeria
Proportion (%) of patients diagnosed using endoscopy, biopsy, or imaging, and median time to diagnosis (days) defined as the interval between first reported symptom and confirmed diagnosis.
Time frame: At Basline (Initial Visit)
Therapeutic management modalities
Proportion (%) of patients receiving surgery, chemotherapy, targeted therapy, immunotherapy, or palliative care, median time from confirmed diagnosis to initiation of first treatment (days), and proportion of patients with documented post-treatment follow-up.
Time frame: At Baseline (Initial Visit)
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Aug 2026, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Société Algérienne de Formation et Recherche en Oncologie